ATE263373T1 - Verfahren und zusammensetzungen zum screenen von modulatoren von sphingosinkinasen - Google Patents

Verfahren und zusammensetzungen zum screenen von modulatoren von sphingosinkinasen

Info

Publication number
ATE263373T1
ATE263373T1 AT01402500T AT01402500T ATE263373T1 AT E263373 T1 ATE263373 T1 AT E263373T1 AT 01402500 T AT01402500 T AT 01402500T AT 01402500 T AT01402500 T AT 01402500T AT E263373 T1 ATE263373 T1 AT E263373T1
Authority
AT
Austria
Prior art keywords
methods
compositions
kinases
sphingosine kinases
screening modulators
Prior art date
Application number
AT01402500T
Other languages
English (en)
Inventor
Emmanuel Normant
Alirio Melendez
Olivier Casamitjana
Francois Moreau
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE263373T1 publication Critical patent/ATE263373T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
AT01402500T 2000-09-29 2001-09-28 Verfahren und zusammensetzungen zum screenen von modulatoren von sphingosinkinasen ATE263373T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00402684A EP1195604A1 (de) 2000-09-29 2000-09-29 Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Lipidkinasen

Publications (1)

Publication Number Publication Date
ATE263373T1 true ATE263373T1 (de) 2004-04-15

Family

ID=8173885

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01402500T ATE263373T1 (de) 2000-09-29 2001-09-28 Verfahren und zusammensetzungen zum screenen von modulatoren von sphingosinkinasen

Country Status (12)

Country Link
US (1) US6723525B2 (de)
EP (2) EP1195604A1 (de)
JP (1) JP2004509638A (de)
AT (1) ATE263373T1 (de)
AU (1) AU2001289939A1 (de)
CA (1) CA2423889A1 (de)
DE (1) DE60102539T2 (de)
DK (1) DK1195605T3 (de)
ES (1) ES2218351T3 (de)
PT (1) PT1195605E (de)
TR (1) TR200400941T4 (de)
WO (1) WO2002027318A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US8945932B2 (en) 2004-07-06 2015-02-03 Perkinelmer Health Sciences, Inc. Methods and compositions for detecting and isolating phosphorylated molecules using hydrated metal oxides
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
EP1913390B1 (de) * 2005-08-11 2012-05-30 PerkinElmer LAS, Inc. Testverfahren unter Verwendung von partikelförmigen Hohlkörpern und diese enthaltende Kits
DE602006012072D1 (de) * 2005-10-12 2010-03-18 Allergan Inc Tests der molekularen oder subzellulären interaktivität unter verwendung von depolarisierung nach resonanzenergietransfer (daret)
EP2586874B1 (de) * 2010-06-28 2015-04-22 Daiichi Sankyo Company, Limited Verfahren zum screening auf s1p-lyase-hemmer mit kultivierten zellen
EP2727926A4 (de) 2011-06-28 2015-03-04 Daiichi Sankyo Co Ltd Phosphorsäure-ester-derivat

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
EP0154734B1 (de) 1984-03-15 1990-08-29 Immunex Corporation Test zur sofortigen Feststellung von Liganden, Testsatz und seine Herstellung
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
EP0502123A4 (en) * 1989-12-01 1992-11-04 Packard Instrument Company, Inc. Scintillation proximity radioimmunoassay using solid scintillator support body
US5677189A (en) * 1995-06-29 1997-10-14 Oncomembrane, Inc. Method for quantifying sphingosine and for diagnosing platelet activation
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
CA2329124A1 (en) * 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
ATE409486T1 (de) * 1998-06-29 2008-10-15 Children S Hospital Los Angele Behandlung hyperproliferativer erkrankungen
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3

Also Published As

Publication number Publication date
EP1195605B1 (de) 2004-03-31
AU2001289939A1 (en) 2002-04-08
EP1195605A1 (de) 2002-04-10
US20020042091A1 (en) 2002-04-11
ES2218351T3 (es) 2004-11-16
TR200400941T4 (tr) 2004-06-21
DE60102539T2 (de) 2005-04-07
DK1195605T3 (da) 2004-08-02
EP1195604A1 (de) 2002-04-10
CA2423889A1 (en) 2002-04-04
JP2004509638A (ja) 2004-04-02
PT1195605E (pt) 2004-08-31
DE60102539D1 (de) 2004-05-06
WO2002027318A1 (en) 2002-04-04
US6723525B2 (en) 2004-04-20

Similar Documents

Publication Publication Date Title
DE60025368D1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
ATE246938T1 (de) Anwendung der mesenchymalen stammzellen als immunsuppressiva
NO20010446L (no) Substituert anilidforbindelser og metoder
DK1311482T3 (da) Ikke-imidazolaryloxypiperidiner som H3-receptorligander
ATE459621T1 (de) Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
DE602005014134D1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
ATE556751T1 (de) Anziehungssystem und verfahren zur bereitstellung der anziehung
BRPI0503397A (pt) composição de coloração, processo de coloração e uso de uma composição
DE602004017486D1 (de) Substituierte heteroarylbenzofuransäuren
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
DE60121928D1 (de) Verfahren zur herstellung von den trans-4-n-butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)-dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung
ATE402211T1 (de) Verfahren zur herstellung von farblosen, lagerstabilen biuretgruppenhaltigen polyisocyanaten
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
DE60102539D1 (de) Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Sphingosinkinasen
DE60033576D1 (de) Methoden zum screening knochenmorphogenetishemimetika
DK1007666T3 (da) Neurturinreceptor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1195605

Country of ref document: EP

REN Ceased due to non-payment of the annual fee